Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing. Go→
News, articles and issues specific to clinical trial practice and implementation at the investigative site level. Go→
Strategies and innovations related to how clinical professionals are utilizing technology internal and external to their organizations to advance clinical trials. Go→
News, articles and issues specific to laboratories role in the clinical trial, including ECG, imaging, genotyping, tissue samples and more. Go→
News, developments and strategies for clinical trials conduct in relation to the FDA, EMEA and other global regulatory authorities overseeing the drug development industry. Go→
News, articles and strategies related to clinical trial design which impact postmarketing studies, therapeutic areas, adaptive trials, statistics, protocols and more. Go→
The European Medicines Agency (EMA) is publishing, for the first time, the agendas of the Committee for Medicinal Products for Human Use (CHMP), the Committee for Medicinal Products for Veterinary Use (CVMP) and the Committee for Advanced Therapies (CAT). The minutes of each of these meetings held in December will be published once they have been adopted by the relevant Committee at its meeting in January. It will then be standard practice to publish the agendas at the start of each meeting and the minutes after their adoption the following month.
This follows last week’s Management Board meeting, which cleared the way for the publication of the agendas and minutes of these three remaining EMA scientific committees. It is the final step of a process launched by the Agency in July 2012 that has already been implemented for its four other scientific committees.
“Openness of our operations is one of my key objectives. As part of this, we promised in July 2012 to start publishing agendas and minutes of all seven of our scientific committees by the end of 2013, and we are now delivering on this objective. Achieving our plan for all committees, including those giving recommendations on the marketing authorisation of medicines, the CHMP and CVMP, is a major milestone in this transparency initiative,” said Guido Rasi, Executive Director of the EMA.
“We see transparency as a priority as it is the basis for public confidence and trust in the Agency and the European Union system for the evaluation of medicines,” he added.
The Agency started publishing the agendas and minutes of its scientific committee meetings with the Pediatric Committee (PDCO) and the Pharmacovigilance Risk Assessment Committee (PRAC) in July 2012, followed by the Committee for Orphan Medicinal Products (COMP) in September 2012 and the Committee on Herbal Medicinal Products (HMPC) in September 2013.